glp 1 dementia 🧐Will GLP-1RA drugs be the future of altzeimers treatement? 🧠There are multiple studies underway assessing the effectiveness of glp-1 class of medications in prevention and/or delay of 🧠Alzheimer's makes up 60%-80% GLP-1 Agonists and Dementia -

Non-human primates, in particular Cynomolgus macaques (long-tailed macaques), were critical in determining how long-acting GLP-1 receptor agonist drugs are metabolised and cleared by the body, helping define proper dosing and delivery methods

Research from National Library of Medicine in 2024 also suggests GLP-1 drugs are linked to adverse gastrointestinal events, including nausea, vomiting, delayed gastric emptying and pancreatitis

Another retrospective study from a VA primary care clinic found 6.3% of the study group discontinued insulin use when they initially started a GLP-1 agonist, and 14.6% of patients discontinued insulin use within the year follow-up [38]

Peptides can aggregate at high concentrations, improper buffer conditions, or due to an imbalance of hydrophobic and hydrophilic properties

That sets up the drug, which will be marketed as Wegovy in a pill, to launch early next year

Importantly, the Jiang et al